Toxicity management of angiogenesis inhibitors: resolution of expert panel
On 22 June 2017 in St. Petersburg the expert panel was held on the topic Management of toxicity of angiogenesis inhibitors, which discussed current issues of systemic therapy of advanced differentiated thyroid cancer resistant to radioactive iodine therapy, advanced kidney cancer and questions of ef...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Endocrinology Research Centre
2017-12-01
|
| Series: | Эндокринная хирургия |
| Subjects: | |
| Online Access: | https://surg-endojournals.ru/serg/article/viewFile/9472/7052 |
| id |
doaj-037598e36cd641619fca790aa082842b |
|---|---|
| record_format |
Article |
| spelling |
doaj-037598e36cd641619fca790aa082842b2021-06-02T21:12:20ZrusEndocrinology Research CentreЭндокринная хирургия2306-35132310-39652017-12-0111315716310.14341/serg20173157-1638389Toxicity management of angiogenesis inhibitors: resolution of expert panelPavel O. Rumiantsev0Maria I. Volkova1Sergey O. Podvyaznikov2Ilya S. Romanov3Elena K. Shavarova4Eugenia A. Shatokhina5Endocrinology Research CentreOncology Research Centre named after N.N. BlokhinOncology Research Centre named after N.N. BlokhinOncology Research Centre named after N.N. BlokhinPeoples Friendship University of RussiaCentral State Medical Academy of the President of Russian FederationOn 22 June 2017 in St. Petersburg the expert panel was held on the topic Management of toxicity of angiogenesis inhibitors, which discussed current issues of systemic therapy of advanced differentiated thyroid cancer resistant to radioactive iodine therapy, advanced kidney cancer and questions of efficacy and safety of new target drugs in the treatment of these diseases. The reports and discussions of experts raised the following questions: 1. Own experience of using lenvatinib in patients with differentiated thyroid cancer refractory to therapy with radioactive iodine and kidney cancer. 2. Profile of efficacy and safety of modern targeted therapy with multikinase inhibitors. 3. Prophylaxis and management of predictable toxicity.https://surg-endojournals.ru/serg/article/viewFile/9472/7052well-differentiated thyroid cancerradiodiodine resistancerenal cancerangiogenesis inhibitorslenvatinib |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
Pavel O. Rumiantsev Maria I. Volkova Sergey O. Podvyaznikov Ilya S. Romanov Elena K. Shavarova Eugenia A. Shatokhina |
| spellingShingle |
Pavel O. Rumiantsev Maria I. Volkova Sergey O. Podvyaznikov Ilya S. Romanov Elena K. Shavarova Eugenia A. Shatokhina Toxicity management of angiogenesis inhibitors: resolution of expert panel Эндокринная хирургия well-differentiated thyroid cancer radiodiodine resistance renal cancer angiogenesis inhibitors lenvatinib |
| author_facet |
Pavel O. Rumiantsev Maria I. Volkova Sergey O. Podvyaznikov Ilya S. Romanov Elena K. Shavarova Eugenia A. Shatokhina |
| author_sort |
Pavel O. Rumiantsev |
| title |
Toxicity management of angiogenesis inhibitors: resolution of expert panel |
| title_short |
Toxicity management of angiogenesis inhibitors: resolution of expert panel |
| title_full |
Toxicity management of angiogenesis inhibitors: resolution of expert panel |
| title_fullStr |
Toxicity management of angiogenesis inhibitors: resolution of expert panel |
| title_full_unstemmed |
Toxicity management of angiogenesis inhibitors: resolution of expert panel |
| title_sort |
toxicity management of angiogenesis inhibitors: resolution of expert panel |
| publisher |
Endocrinology Research Centre |
| series |
Эндокринная хирургия |
| issn |
2306-3513 2310-3965 |
| publishDate |
2017-12-01 |
| description |
On 22 June 2017 in St. Petersburg the expert panel was held on the topic Management of toxicity of angiogenesis inhibitors, which discussed current issues of systemic therapy of advanced differentiated thyroid cancer resistant to radioactive iodine therapy, advanced kidney cancer and questions of efficacy and safety of new target drugs in the treatment of these diseases. The reports and discussions of experts raised the following questions: 1. Own experience of using lenvatinib in patients with differentiated thyroid cancer refractory to therapy with radioactive iodine and kidney cancer. 2. Profile of efficacy and safety of modern targeted therapy with multikinase inhibitors. 3. Prophylaxis and management of predictable toxicity. |
| topic |
well-differentiated thyroid cancer radiodiodine resistance renal cancer angiogenesis inhibitors lenvatinib |
| url |
https://surg-endojournals.ru/serg/article/viewFile/9472/7052 |
| work_keys_str_mv |
AT pavelorumiantsev toxicitymanagementofangiogenesisinhibitorsresolutionofexpertpanel AT mariaivolkova toxicitymanagementofangiogenesisinhibitorsresolutionofexpertpanel AT sergeyopodvyaznikov toxicitymanagementofangiogenesisinhibitorsresolutionofexpertpanel AT ilyasromanov toxicitymanagementofangiogenesisinhibitorsresolutionofexpertpanel AT elenakshavarova toxicitymanagementofangiogenesisinhibitorsresolutionofexpertpanel AT eugeniaashatokhina toxicitymanagementofangiogenesisinhibitorsresolutionofexpertpanel |
| _version_ |
1721400771850797056 |